CVS HEALTH Corp (CVS) stock

CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 19/3031% below fair value

$89.79+0.27 (+0.30%)

Close on Nov 12, 2026Market cap $114.84BP/E 10.5Yield 2.96%

Cvs Health statistics

110 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Feb 9, 2027 (estimated, before the open)
Last ex-dividend date: Jul 23, 2026
Fundamentals through: Sep 30, 2026
Share price as of: Nov 11, 2026

Valuation ratiosIndustry

Market Cap: $114.49B; $369.78M
Enterprise Value: $160.48B; $383.70M
PE Ratio: 10.43; 16.07
PS Ratio: 0.27; 0.55
PB Ratio: 1.42; 1.96
P/FCF Ratio: 7.35; 16.38
P/OCF Ratio: 6.12; 10.56

Enterprise valuationIndustry

EV / Sales: 0.38; 0.56
EV / EBITDA: 8.20; 12.63
EV / EBIT: 10.66; 13.92
EV / FCF: 10.31; 18.03

Share statisticsIndustry

Shares Outstanding: 1.28B; 41M
Shares Change (YoY): 1.54%; 1.85%
Shares Change (QoQ): 0.16%; 0.08%
Float: 1.27B; 36M
Shares Held by Insiders: 0.43%; 8.39%
Shares Held by Institutions: 89.2%; 43.9%

Short sellingIndustry

Short Interest: 18M; –
Short Interest Change: 10.4%; -1.30%
Short % of Float: 1.40%; 7.56%
Short % of Shares Outstanding: 1.40%; 5.07%
Days to Cover: 2.78; 4.89

Stock price statisticsIndustry

52-Week High: $110.68; –
52-Week Low: $69.51; –
20-Day Moving Average: $89.84; –
50-Day Moving Average: $89.97; –
200-Day Moving Average: $89.02; –
Average True Range (14): $3.16; –
Price Change (1 Week): 12.0%; -0.96%
Price Change (1 Month): 2.25%; 2.79%
Price Change (3 Months): -5.76%; -11.8%
Price Change (6 Months): -8.76%; -10.2%
Price Change (YTD): 12.8%; -21.2%
Price Change (1 Year): 15.5%; -11.7%
Price Change (3 Years): 32.0%; 2.15%
Price Change (5 Years): -4.79%; -69.9%
Price Change (10 Years): 19.2%; 33.9%
Average Volume (10 Days): 16M; –
Average Volume (20 Days): 11M; –
Average Volume (90 Days): 9M; –
Relative Volume: 1.28; 0.62
Relative Strength Index (14): 51.4; 52.3
Volatility (1 Year): 34.1%; 65.8%
Beta (5 Years): 0.49; 1.10

MarginsIndustry

Gross Margin: 44.2%; 39.8%
Operating Margin: 3.58%; -0.00%
Pretax Margin: 2.88%; -0.43%
Profit Margin: 2.62%; -0.21%
EBITDA Margin: 4.66%; 1.22%
FCF Margin: 3.70%; 1.47%

Returns on capitalIndustry

Return on Equity (ROE): 14.4%; -4.22%
Return on Assets (ROA): 4.30%; -1.49%
Return on Invested Capital (ROIC): 10.8%; -1.77%
Return on Capital Employed (ROCE): 9.13%; 2.23%

Financial positionIndustry

Current Ratio: 0.85; 1.16
Quick Ratio: 0.61; 0.44
Debt / Equity: 0.75; 0.64
Debt / EBITDA: 3.10; 2.78
Debt / FCF: 3.90; 3.75
Net Debt / EBITDA: 2.34; 1.47
Interest Coverage: 4.91; -0.18

GrowthIndustry

Revenue Growth (YoY): 6.73%; 6.73%
Net Income Growth (YoY): 2253.3%; 30.3%
EPS Growth (YoY): 2157.9%; 12.2%
FCF Growth (YoY): 147.4%; -7.45%
Revenue Growth (3Y CAGR): 7.63%; -1.38%
Revenue Growth (5Y CAGR): 8.39%; 4.80%
EPS Growth (3Y CAGR): -24.7%; -1.16%
EPS Growth (5Y CAGR): -23.9%; 8.06%

EfficiencyIndustry

Asset Turnover: 1.64; 1.46
Inventory Turnover: 12.61; 5.87
Revenue Per Employee: $1.40M; $404.74K
Profits Per Employee: $36.79K; -$2.22K
Employee Count: 300,000; 445
WACC: 6.42%; 9.18%

Income statement (TTM)Industry

Revenue: $420.61B; $351.39M
Gross Profit: $186.06B; $247.20M
Operating Income: $15.06B; -$128.01K
Pretax Income: $12.12B; -$578.22K
Net Income: $11.04B; -$578.22K
EBITDA: $19.58B; $185.52K
EPS (Diluted): $8.58; $0.00

Balance sheetIndustry

Cash & Short-Term Investments: $14.89B; $21.81M
Total Debt: $60.68B; $101.86M
Net Cash (Debt): -$45.79B; $10.47K
Net Cash Per Share: -$35.80; $0.00
Equity (Book Value): $80.50B; $21.07M
Book Value Per Share: $62.94; $0.78
Tangible Book Value: -$29.21B; $1.97M
Working Capital: -$13.71B; $2.15M

Cash flow (TTM)Industry

Operating Cash Flow: $18.71B; $1.51M
Capital Expenditures: -$3.14B; -$13.63M
Free Cash Flow: $15.57B; $2.88M
FCF Per Share: $12.17; $0.12

Dividends and yieldsIndustry

Earnings Yield: 9.64%; 2.60%
FCF Yield: 13.6%; 2.93%
Dividend Yield: 2.97%; 0.97%
Shareholder Yield: 2.97%; 1.52%
Dividend Per Share: $2.66; $1.28
Dividend Growth (YoY): 0.00%; 9.59%
Years of Dividend Growth: 0; 0
Payout Ratio: 31.0%; 25.7%
FCF Payout Ratio: 22.0%; 28.2%

Taxes and interestIndustry

Interest Expense: $3.07B; $1.99M
Income Tax: $1.07B; $1.14M
Effective Tax Rate: 8.85%; 22.2%

Scores and fair valueIndustry

Graham Number: $110.23; $20.77
Graham Upside: 23.1%; -24.6%
Altman Z-Score: 2.51; 2.09
Piotroski F-Score: 7; 5

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	CVS	S&P 500	Difference	CVS per year	S&P 500 per year
1 month	+2.3%	-2.7%	+5.0 pts
3 months	-5.2%	-1.7%	−3.5 pts
Year to date	+15.8%	+11.9%	+3.9 pts
1 year	+14.5%	+12.0%	+2.5 pts
3 years	+47.5%	+78.2%	−30.7 pts	+13.8%	+21.2%
5 years	+12.1%	+73.2%	−61.2 pts	+2.3%	+11.6%
10 years	+62.0%	+309.6%	−247.6 pts	+4.9%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

18M CVS shares were sold short on Oct 30, 2026, up 10.4% from the previous report, or 1.40% of the shares available to trade. At recent volumes it would take 2.8 days to buy them back. Over the last 20 sessions, 26.9% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	17,875,527	+10.4%	6,421,152	2.8
Oct 15, 2026	16,193,404	-1.7%	10,334,989	1.6
Sep 30, 2026	16,470,151	+2.1%	9,936,300	1.7
Sep 15, 2026	16,123,980	-11.0%	5,132,435	3.1
Aug 31, 2026	18,114,651	+7.7%	6,457,753	2.8
Aug 14, 2026	16,823,735	-9.9%	9,344,565	1.8
Jul 31, 2026	18,676,470	-4.3%	7,743,941	2.4
Jul 15, 2026	19,524,883	-2.1%	7,190,543	2.7
Jun 30, 2026	19,938,997	-14.0%	8,647,548	2.3
Jun 15, 2026	23,194,154	+30.6%	8,557,677	2.7
May 29, 2026	17,760,492	-9.0%	7,445,329	2.4
May 15, 2026	19,520,276	+9.6%	9,894,225	2.0